The impact of the ?cisplatin era? of treatment on survival in testicular cancer

Abstract

The records of all testicular cancer patients evaluated and treated at our medical center during two consecutive 9-year periods were reviewed and analyzed for prognostic factors, particularly the impact of cisplatin-based combination chemotherapy. The data base of 244 patients was divided into two eras: 1970-1978, defined as the "pre-cisplatin era" (n = 101) and 1979-1987, the "cisplatin era" (n = 143). Statistically improved survival (P = 0.024) was noted for the 165 nonseminoma patients and for a grouping of 143 patients treated with combination chemotherapy (P = 0.004) during the cisplatin era. Stratification by stage revealed that stage II patients had the most significant survival advantage (P = 0.001) during the cisplatin era; cancer mortality improved from 48°7o to 9°70. Cancer death rates for stage III patients decreased from 58% to 39°7o which is clinically but not statistically significant (P = 0.497). Stage I patients and the seminoma population did well during both eras, and the impact of cisplatin could not be statistically confirmed in this study for these subgroups. Multivariate statistical analysis confirmed the importance of the era of treatment for the nonseminoma population.The improved outlook for testicular cancer patients has been widely touted in the urologic and oncologic literature [1, 2, 4-6, 10, 11, 13, 14, 18-25]. There is no question that tremendous progress has been made with patients treated under protocol settings and by experts in the field at centers that treat a high volume of such patients. We sought to address the question as to whether this improved outlook could be expected in all patients treated by a variety of physicians and not necessarily under protocol conditions. We therefore reviewed our entire experience with all testicular cancer patients seen over an 18-year period; we not only analyzed the composite pop-

Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors

“…Overall, the prognosis of the disease is good, with five-year overall-survival rates over 95%, and most patients are effectively treated even in the event of metastasized disease, which is in great part due to the high sensitivity of these tumors to platin-based chemotherapy [ 5 , 6 ]. However, major clinical challenges in the field persist.…”

A Coculture Model Mimicking the Tumor Microenvironment Unveils Mutual Interactions between Immune Cell Subtypes and the Human Seminoma Cell Line TCam-2

“…Testicular germ cell cancer (TGCC) is the most common malignancy in young men [ 1 ]. Based on its histopathology, TGCC can be subdivided into seminomas and the more heterogeneous group of non-seminomas, both types with quite similar incidences but significant differences in treatment and prognosis [ 2 , 3 , 4 , 5 ]. In general, TGCC show extremely high cure rates as a consequence of primary surgery and a combination with effective platin-based chemotherapy in advanced stages of cancer.…”

Proteomic profiling of cisplatin-resistant and cisplatin-sensitive germ cell tumour cell lines using quantitative mass spectrometry

“…Subsequent cisplatin-based combination chemotherapy is required in metastatic GCTs [5,6]. The introduction of cisplatinbased combination chemotherapy has led to cure rates of up to 90% even in metastatic disease stages [7][8][9]. Teratomas are of particular interest, as they are uniformly cisplatinresistant and surgery is the only successful therapy [6].…”